Novartis taps celeb dancer and ‘Ellen’ show DJ to headline Adakveo social challenge
So you think you can dance—for Adakveo? Novartis’ latest campaign asks people to bust a move to raise awareness around sickle cell anemia and its...
Marketing
4 AbbVie brands land on pharma’s top TV spenders list for September
Pharma TV advertising spiked in September, even without the usually ubiquitous football media to play it on. The top 10 brands spent $182 million, the highest monthly...
Merck CEO calls on private industry to ‘stabilize society’ amid racial injustice, economic downturn
In a tumultuous 2020, the COVID-19 pandemic and simmering racial protests have exposed gaps between the ideal America some of its citizens see and the...
Merck’s Keytruda scores solo lymphoma nod, but analysts are fixed on Seagen’s combo potential
Merck & Co.’s Keytruda has won a new place on the previously treated classical Hodgkin lymphoma market—but now it has to carve out market share. And...
Roche hit by ‘high-end’ biosimilar attack as Ocrevus, Tecentriq bounce back from COVID slowdown
Biosimilars historically haven’t enjoyed the same success in the U.S. as in Europe. So industry watchers weren’t exactly sure how copycats to Roche’s big three cancer...
Seagen, Astellas eye earlier Padcev use in bladder cancer with long-lasting phase 2 results
Right now, Seagen and Astellas’ Padcev is cleared only for metastatic bladder cancer patients who have already received chemo and a checkpoint inhibitor from the...
Pfizer’s Ibrance kisses early breast cancer hopes goodbye with second study failure
After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a...
Eli Lilly’s Olumiant pares COVID-19 patients’ recovery time down to 7 days as an add-on to remdesivir
Months into the COVID-19 pandemic, just two therapies have emerged as FDA-approved emergency therapies for hospitalized patients. Last month, Eli Lilly rolled out findings for...
Ironwood, AbbVie add ‘bloating’ and ‘discomfort’ to Linzess label to reach more IBS-C patients
Ironwood and AbbVie can now add “bloating” and “discomfort” to marketing for irritable bowel syndrome with constipation (IBS-C) drug Linzess, thanks to a supplemental NDA approval...
Animal Genetics Market Shaping from Growth to Value | Zoetis, CRV Holding, Grimaud
Animal Genetics Market A new business intelligence report released by HTF MI with title “Global Animal Genetics Market Size, Status and Forecast 2019-2025” is designed...